Ipilimumab (Yervoy®)

• Class: Immune checkpoint inhibitor (CTLA-4 inhibitor)
• Mechanism: Blocks CTLA-4, enhancing T-cell activation and immune response against tumors
• Indications:
  • Melanoma (adjuvant and metastatic)
  • In combination with nivolumab for RCC, NSCLC, mesothelioma, etc.
• Dosing:
  • IV, commonly 3 mg/kg q3w x 4 doses (in combo regimens; varies)
• Key Toxicities:
  • Immune-related adverse events (irAEs):
    • Colitis, hepatitis, dermatitis, endocrinopathies (especially hypophysitis, thyroiditis)
  • Requires high-dose corticosteroids for management of severe irAEs
• Monitoring:
  • LFTs, TSH, ACTH/cortisol, glucose, GI symptoms

Synonyms

Ipilimumab, Yervoy

Links